TPIV 110

Drug Profile

TPIV 110

Alternative Names: TPIV110

Latest Information Update: 03 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mayo Clinic
  • Developer Mayo Clinic; TapImmune
  • Class Antigens; Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Breast cancer

Most Recent Events

  • 14 Mar 2017 Mayo Clinic and TapImmune plan a phase Ib/IIa trial in Breast cancer (ductal carcinoma in situ) in USA
  • 01 Nov 2016 TapImmune plans to submit an amended IND application to the US FDA for Breast cancer
  • 01 Nov 2016 TapImmune plans a phase II trial for Breast Cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top